



Deciphera Pharmaceuticals to Present Data on its Highly-Selective Small Molecule CSF1R Immunokinase Inhibitor, DCC-3014, at American Association for Cancer Research Annual Meeting 2016

March 17, 2016

Presentation of Preclinical Data on Efficacy of DCC-3014, a potent macrophage checkpoint inhibitor, as both single agent and in combination with an anti-PD1 inhibitor

Deciphera Pharmaceuticals, a clinical-stage biotechnology company focused on developing advanced kinase inhibitor treatments targeting the tumor cell and the tumor microenvironment, today announced that an abstract highlighting the company's highly-selective small molecule CSF1R inhibitor, DCC-3014, has been selected for presentation at the American Association for Cancer Research Annual Meeting 2016, taking place April 16-20, 2016 in New Orleans. DCC-3014 was designed as a highly-specific macrophage immunomodulatory agent based on the company's Switch Control Inhibitor platform. In preclinical cancer models, DCC-3014 was shown to significantly enhance anti-tumor activity when used in combination with an anti-PD-1 checkpoint inhibitor. Deciphera expects to initiate a Phase 1 clinical trial of DCC-3014 in the second half of 2016.

"We are pleased to present data at the AACR Annual Meeting 2016 demonstrating DCC-3014's robust inhibition of the CSF1R kinase, both as a single agent and in

combination with an anti-PD1 inhibitor, across a number of cancer models,” said Michael D. Taylor, Ph.D., Deciphera's President and Chief Executive Officer. “We look forward to initiating the first-in-human Phase 1 trial with DCC-3014 later this year.”

Details of the Poster Presentations on DCC-3014:

Poster Title: The highly specific CSF1R inhibitor DCC-3014 exhibits immunomodulatory and anti-invasive activities in cancer models

Author: Smith, Bryan D.

Abstract #: 4889

Session: Immune Modulating Agents 2

Date & Time: Wednesday, April 20, 2016, 8:00 AM – 12:00 PM

Location: Halls G-J, Poster Section 2. Poster Board #30

Contacts:

Michael D. Taylor, Ph.D., Deciphera Pharmaceuticals

mtaylor@deciphera.com

781-209-6411

Media:

Gina Nugent, The Yates Network

gina@theyatesnetwork.com

617-460-3579